$GPCR News

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030

Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now

Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)

HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70

Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron

Does Phase 2b Oral GLP-1 Data on Aleniglipron Change The Bull Case For Structure Therapeutics (GPCR)?

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Structure Therapeutics Publishes Phase 2b Aleniglipron Results In Nature Medicine, Reporting Up To 16.2% Weight Loss; Phase 3 Obesity Program On Track For Q3 2026

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics Amends And Restates Sales Agreement With Leerink Partners LLC And Cantor Fitzgerald & Co. On May 7, 2026; Increases ATM Shares Offering By $150M To Aggregate $400M

Structure Therapeutics Q1 EPS $(0.35), Inline

Why Structure Therapeutics (GPCR) Is Down 7.2% After Strong Oral GLP-1 Phase 2 Data And FDA Plans

Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at